We use cookies to improve the functionality and performance of this site. By continuing to use this site, you are providing us with your consent to our use of cookies on the site. Please see our Privacy Policy for details.

Team Experience Thought Leadership About Press Room Locations Careers
Related Sites
MWE China Law Offices McDermott+Consulting
MENU McDermott Will & Emery
Languages
Deutsch English Français Italiano
McDermott Will & Emery
Team Experience Thought
Leadership
About Press
Room
Locations Careers
Languages
Deutsch English Français Italiano

Experience / Life Sciences / Licensing & Collaborative Arrangements

Connect Share pdf your pages
  • {{page.name}}
  • Linked In
    Linked In
  • Xing
    Xing
  • Twitter
    Twitter
  • Facebook
    Facebook
  • Email This
    Email This
  • PDF
    PDF
  • Print
    Print

Licensing & Collaborative Arrangements

{{navLabel}}
  • Overview
  • Results
  • Team
  • Press Room

Overview

For participants in life sciences, maximizing its proprietary knowledge is often the next step in corporate growth, and can sometimes be vital for a company’s survival. Navigating the opportunities to select the ideal partner for licensing and efforts to collaborate can be daunting. Understanding, and balancing, short term needs with protection long-term goals requires skilled counsel to assist with structuring such an arrangement.

McDermott’s life sciences lawyers help pharmaceutical, biotechnology and medical device clients on a wide variety of licensing, strategic alliance and partnering transactions, integrating the knowledge and experience of lawyers from many of the firm’s key practices such as corporate transactions, health care regulatory, antitrust and tax. We implement complex, cross-border transactions by leveraging the firm’s strong international presence in the United States, Europe and Asia. Our work is expansive covering research and development agreements, joint venture formation and control, manufacturing and supply arrangements, commercialization agreements, and technology evaluation and option agreements.

Our clients come from every sector of the industry and range from small, private and emerging venture-backed companies to large, public corporations and multinational enterprises. We understand that no licensing, research collaboration or joint venture agreement arises in a vacuum, and advise clients at every step in the process, including developing strategic structures, drafting and negotiating letters of intent, term sheets and definitive agreements, preparing and reviewing regulatory filings, managing alliances and resolving disputes.

Key Contacts

  • DeStefano Paul

    Paul R. DeStefano

    Counsel Silicon Valley
  • Smith Richard B

    Richard B. Smith

    Partner Boston
  • Hogan, Sarah T.

    Sarah T. Hogan

    Partner Boston

Results

  • Baxter BioScience, a division of Baxter International Inc., in the negotiation of a license and collaboration agreement valued at nearly $1 billion with Merrimack Pharmaceuticals for the ex-US development and commercialization of MM-398, a clinical-stage oncology candidate intended for the treatment of pancreatic cancer
  • Innate Pharma, a major French life sciences company, on a $1.275 billion partnership - among the largest ever in the French biotech industry – with AstraZeneca to accelerate development of Innate Pharma’s IPH2201 antibody designed to stimulate the body's immune system to destroy cancer cells
  • 23andMe, a privately held genomics and biotechnology company, on the legal aspects of a transaction with Genentech, whereby Genentech was given exclusive access to our client’s database of almost 1 million whole genetic sequences for the study of potential genetic targets for Parkinson’s Disease.
  • Servier Monde, a French pharmaceutical laboratory, on its strategic partnership with Intarcia Therapeutics to develop and commercialize ITCA 650, Intarcia’s phase 3 investigational therapy for the treatment of type 2 diabetes, outside of the United States and Japan
  • PharmAbcine, based in Seoul, Korea, with its exclusive license agreement with TriPhase Research and Development II Corporation involving a PharmAbcine compound potentially useful in the treatment of cancer
  • Seikagaku Corporation in it licensing agreement with the University of British Columbia for its recombinant means of producing limulus-derived lysates
  • Amunix in sponsored research and license agreements with each of Biogen Idec and Eli Lilly and Company regarding coagulation factors
  • Biocon in its strategic global agreement with Pfizer for biosimilar versions of insulin and analog products

Team

  • {{result.FullName}}
    Default Photo

    {{result.FullName}}

    {{result.LevelDisplayName}}
    {{result.Level}}
    Email
    {{office.name}} t: {{office.phone}}
  • View More

Press Room

All Press Releases Coverage Accolades Coverage
  • {{newsItem.title}}
    {{newsItem.title}}
    {{newsItem.title}}

    {{newsItem.publicationName}} {{newsItem.displayDate}}
    {{newsItem.listingImageAlternateText}}
  • View More
  • {{newsItem.title}}

    {{newsItem.publicationName}} {{newsItem.displayDate}}
    {{newsItem.listingImageAlternateText}}
  • View More
  • {{newsItem.title}}

    {{newsItem.publicationName}} {{newsItem.displayDate}}
    {{newsItem.listingImageAlternateText}}
  • View More
  • {{newsItem.title}} {{newsItem.title}}

    {{newsItem.publicationName}} {{newsItem.displayDate}}
    {{newsItem.listingImageAlternateText}}
  • View More
  • {{newsItem.title}} {{newsItem.title}}

    {{newsItem.publicationName}} {{newsItem.displayDate}}
    {{newsItem.listingImageAlternateText}}
  • View More
Fueling Your Mission

Related Sectors

  • Life Sciences
  • Food, Drug & Medical Device Regulatory
  • Life Sciences Intellectual Property
  • Life Sciences - Mergers & Acquisitions
  • Life Sciences - Regulatory

© 2018 McDermott Will & Emery

Alumni Legal Notices Imprint Privacy and Cookies Policy Client Connect Connect@McDermott Contact Us
Related Sites MWE China Law Offices McDermott+Consulting
Attorney Advertising